Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Treatment of non-cutaneous mature T-cell lymphoma (PTCL) remains difficult. Results of the AATT study (Schmitz et al. Blood 2021) demonstrated that standard 1st line chemotherapy followed by alloSCT did not improve outcome of PTCL patients (pts) when compared to autoSCT. We sought to investigate long-term outcomes of AATT patients focusing on the role of alloSCT in pts transplanted on and off study.
Introduction: The best treatment for young patients with high-risk diffuse large B-cell lymphoma (DLBCL) is still a matter of debate. Results of the phase 3 R-MegaCHOEP study showed promising results using etoposide in combination with R-CHOP (R-CHOEP). Progression-free (PFS) and overall survival (OS) rates for young patients (18–60 years) with high-risk (age-adjusted IPI 2, 3) DLBCL treated with R-CHOEP were among the best reported for such patients.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
